Intervention not reported
Episodes of diarrhoea · children
The intervention leads to lower episodes of diarrhoea (high certainty).
1 finding from 1 review
- IRR 0.7 [0.58, 0.85]9 studies · 4664 participantsHigh
Findings
What do systematic reviews say?
1,444 questions · 1,518 findings · 135 reviews · Infectious Diseases
No studies found 135 · 8.9%GRADE not reported 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%
Intervention not reported
Episodes of diarrhoea: rate ratios · children up to 15 years of age
The intervention probably leads to lower episodes of diarrhoea: rate ratios (moderate certainty).
1 finding from 1 review
- rate ratio 0.71 [0.62, 0.81]9 studies · 15950 participantsModerate
Intervention not reported
Episodes of diarrhoea · adults with AIDS
The intervention showed no clear difference in episodes of diarrhoea (moderate certainty).
1 finding from 1 review
- Mean difference 1.681 study · 148 participantsModerate
Intervention not reported
Hand‐washing behavioural changes/changes in knowledge, attitude and practice · adults with AIDS
1 finding from 1 review
- no estimate extracted1 study · 1 participantsModerate
Atovaquone‐proguanil vs artemether‐lumefantrine (AL)
Total failure: day 28 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 5 [0.25, 99.95]1 study · 60 participantsLow
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil
Total failure day 28 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 15.48 [0.9, 267.27]1 study · 187 participantsLow
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure [day 42 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 1.84 [0.95, 3.56]2 studies · 1258 participantsModerate
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 1.56 [0.88, 2.79]1 study · 1063 participantsModerate
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil
Early treatment failure · children and adults
Atovaquone‐proguanil showed no clear difference in early treatment failure compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 5.11 [0.25, 104.94]2 studies · 395 participantsLow
Atovaquone‐proguanil vs artemether‐lumefantrine (AL)
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 5 [0.25, 99.95]1 study · 60 participantsLow
Atovaquone‐proguanil vs artemether‐lumefantrine (AL)
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 3 [0.19, 47.12]1 study · 208 participantsLow
Atovaquone‐proguanil vs artesunate‐amodiaquine (AS‐AQ)
Total failure: day 28 (PCR‐adjusted) · children under 5 years of age
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐amodiaquine (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 3.19 [0.67, 15.22]1 study · 132 participantsLow
Atovaquone‐proguanil vs artesunate‐amodiaquine (AS‐AQ)
Total failure day 28 PCR‐unadjusted · children under 5 years of age
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐amodiaquine (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 1.2 [0.49, 2.91]1 study · 132 participantsLow
Atovaquone‐proguanil vs artesunate‐amodiaquine (AS‐AQ)
Early treatment failure · children under 5 years of age
Atovaquone‐proguanil showed no clear difference in early treatment failure compared with artesunate‐amodiaquine (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 13.8 [0.79, 240.11]1 study · 132 participantsLow
Atovaquone‐proguanil vs mefloquine plus artesunate (MQ + AS)
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artesunate‐mefloquine (high certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 1.15 [0.57, 2.34]2 studies · 1168 participantsHigh
Atovaquone‐proguanil vs mefloquine plus artesunate (MQ + AS)
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐mefloquine (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 0.8 [0.5, 1.3]1 study · 1063 participantsLow
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil
Total failure: day 28 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 5.143 [0.61, 43.52]2 studies · 375 participantsLow
Rotarix vs placebo
Severe cases of rotavirus diarrhoea · children
Rotarix leads to lower severe cases of rotavirus diarrhoea compared with placebo (high certainty).
6 findings from 1 review
- RR 0.07 [0.03, 0.18]4 studies · 14976 participantsHigh
- RR 0.42 [0.28, 0.61]4 studies · 15822 participantsHigh
- RR 0.65 [0.51, 0.83]2 studies · 13768 participantsModerate
Show 3 more findings
- RR 0.1 [0.07, 0.14]6 studies · 18145 participantsHigh
- RR 0.21 [0.16, 0.29]4 studies · 31671 participantsHigh
- RR 0.23 [0.17, 0.29]3 studies · 23834 participantsHigh
Rotarix vs placebo
Severe cases of all‐cause diarrhoea · children
Rotarix leads to lower severe cases of all‐cause diarrhoea compared with placebo (high certainty).
6 findings from 1 review
- RR 0.64 [0.52, 0.79]2 studies · 26479 participantsHigh
- RR 0.74 [0.5, 1.09]2 studies · 23317 participantsLow
- RR 0.73 [0.56, 0.95]2 studies · 5639 participantsHigh
Show 3 more findings
- RR 0.83 [0.72, 0.96]1 study · 2764 participantsHigh
- RR 0.48 [0.37, 0.61]1 study · 3874 participantsModerate
- RR 0.49 [0.4, 0.6]2 studies · 6269 participantsModerate
Rotarix vs placebo
All‐cause death · children
Rotarix showed no clear difference in all‐cause death compared with placebo (moderate certainty).
3 findings from 1 review
- RR 1.27 [0.89, 1.81]9 studies · 77043 participantsModerate
- RR 0.88 [0.63, 1.21]11 studies · 8374 participantsModerate
- RR 0.71 [0.17, 2.88]10 studies · 20361 participantsLow